The Latin America, Middle East and Africa Bispecific Antibodies Market would witness market growth of 50.3% CAGR during the forecast period (2023-2030).
Bispecific antibodies are becoming increasingly in demand, and as more international pharmaceutical companies enter the market, so does competition amongst businesses to stay ahead of the competition. Numerous of these businesses are investing in the creation of innovative bispecific antibody forms that are anticipated to have improved efficacy, stability, and specificity. It is anticipated that this investment in R&D would spur innovation in the domain of bispecific antibodies, ultimately leading to the introduction of brand-new, cutting-edge medicines.
According to the National Library of Medicine, over 100 BsAbs were under clinical evaluation in 2022. These were being evaluated for their efficacy in cancer treatment. Antibody engineers have been motivated to increase the effectiveness of these molecules by the clinical and financial triumphs achieved by rituximab, trastuzumab, cetuximab, and other mAbs. Thus, a new wave of antibodies with modified Fc resulting in considerably stronger effector capabilities, like complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity, is being tested in the clinic, and numerous approvals are anticipated soon. Bispecific antibodies can help by targeting two separate disease mediators concurrently, rerouting T-cells to tumor cells, inhibiting 2 different signaling pathways at the same time, as well as delivering payloads to targeted areas due to their dual specificity.
The prevalence of cancer is increasing in LAMEA. It was projected that each year in Latin America, 1.5 million new instances of cancer and 700,000 cancer deaths occur. Incidence and death rates were correspondingly 186.5 and 86.6 per 100 000 (age-standardized). Prostate cancer accounted for 15% of all new instances of cancer in Latin America and the Caribbean in 2020, followed by breast cancer, colorectal cancer, lung cancer, and stomach cancer, excluding non-melanoma skin cancers. Even though rates varied greatly between nations, lung cancer remained the major cause of cancer death (12% of all cancer fatalities). Consequently, the region offers the market substantial potential opportunities.
The Brazil market dominated the LAMEA Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,456.6 million by 2030. The Argentina market is estimated to grow at a CAGR of 51.2% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 49.9% during (2023 - 2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Bispecific Antibodies Market is Projected to reach USD 80.2 Billion by 2030, at a CAGR of 40.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Cancer
- Inflammatory & Autoimmune Disorder
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Bispecific Antibodies Market, by Indication
1.4.2 LAMEA Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. LAMEA Bispecific Antibodies Market by Indication
4.1 LAMEA Cancer Market by Country
4.2 LAMEA Inflammatory & Autoimmune Disorder Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Bispecific Antibodies Market by Country
5.1 Brazil Bispecific Antibodies Market
5.1.1 Brazil Bispecific Antibodies Market by Indication
5.2 Argentina Bispecific Antibodies Market
5.2.1 Argentina Bispecific Antibodies Market by Indication
5.3 UAE Bispecific Antibodies Market
5.3.1 UAE Bispecific Antibodies Market by Indication
5.4 Saudi Arabia Bispecific Antibodies Market
5.4.1 Saudi Arabia Bispecific Antibodies Market by Indication
5.5 South Africa Bispecific Antibodies Market
5.5.1 South Africa Bispecific Antibodies Market by Indication
5.6 Nigeria Bispecific Antibodies Market
5.6.1 Nigeria Bispecific Antibodies Market by Indication
5.7 Rest of LAMEA Bispecific Antibodies Market
5.7.1 Rest of LAMEA Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 LAMEA Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bispecific Antibodies Market
TABLE 4 Trials and Approvals – Bispecific Antibodies Market
TABLE 5 Acquisition and Mergers– Bispecific Antibodies Market
TABLE 6 LAMEA Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 7 LAMEA Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 8 LAMEA Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 LAMEA Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 LAMEA Inflammatory & Autoimmune Disorder Market by Country, 2019 - 2022, USD Million
TABLE 11 LAMEA Inflammatory & Autoimmune Disorder Market by Country, 2023 - 2030, USD Million
TABLE 12 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 13 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 14 LAMEA Bispecific Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 15 LAMEA Bispecific Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 16 Brazil Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 17 Brazil Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 18 Brazil Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 19 Brazil Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 20 Argentina Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 21 Argentina Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 22 Argentina Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 23 Argentina Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 24 UAE Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 25 UAE Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 26 UAE Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 27 UAE Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 28 Saudi Arabia Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 29 Saudi Arabia Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 30 Saudi Arabia Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 31 Saudi Arabia Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 32 South Africa Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 33 South Africa Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 34 South Africa Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 35 South Africa Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 36 Nigeria Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 37 Nigeria Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 38 Nigeria Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 39 Nigeria Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 40 Rest of LAMEA Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 41 Rest of LAMEA Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 42 Rest of LAMEA Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 43 Rest of LAMEA Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 44 Key Information – Amgen, Inc.
TABLE 45 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 46 Key Information – Pfizer, Inc.
TABLE 47 Key Information – Akeso, Inc.
TABLE 48 Key information –Johnson & Johnson
TABLE 49 key Information – Taisho Pharmaceuticals Holding Co., Ltd.
TABLE 50 Key Information – Immunocore Holdings plc
TABLE 51 Key Information – GlaxoSmithKline PLC
TABLE 52 Key Information – Novartis AG
TABLE 53 Key Information – Allergan PLC
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
FIG 5 LAMEA Bispecific Antibodies Market share by Indication, 2022
FIG 6 LAMEA Bispecific Antibodies Market share by Indication, 2030
FIG 7 LAMEA Bispecific Antibodies Market by Indication, 2019 - 2030, USD Million
FIG 8 LAMEA Bispecific Antibodies Market share by Country, 2022
FIG 9 LAMEA Bispecific Antibodies Market share by Country, 2030
FIG 10 LAMEA Bispecific Antibodies Market by Country, 2019 - 2030, USD Million
FIG 11 Recent strategies and developments: Johnson & Johnson